Patients with Crohn'
Conditions
Interventions
Polaprezinc administration group: patients has Polaprezinc 150mg/day for xxx months with Crohn'
s disease maintenance therapy.
Polaprezinc non administration group: patients treated with Crohn'
s disease maintenance therapy only.
Sponsors
Kawasaki Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Crohn's disease patients who have no change treatments for these three months in remission stage. Able to provide informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients who had undergone total parental nutrition. 2)Patients with serious liverdysfunction and renaldysfunction 3)Patients with serious heart disease ,lung disease and hemo? 4)Patients with malignancy 5)Patients who has a allergic history against Polaprezinc 6)Patients who are pregnant or have the possibility of pregnancy 7)The patient who was judged for unsuitable by responsibility doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Crohn's disease activity index at 0,1,3,6,12 months after treatment and 1 month after end point. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate Evaluation of subjective symptoms QOL(F-8) safty change of labolatory data | — |
Countries
Japan
Outcome results
None listed